Related Experiment Videos
A prospective randomized trial of Duraflo II heparin-coated circuits in cardiac reoperations
P M McCarthy1, J P Yared, R C Foster
1Department of Thoracic & Cardiovascular Surgery, The Cleveland Clinic Foundation, Ohio 44195, USA. mccartp@cesmtp.ccf.org
Insights
Heparin-coated circuits in cardiac reoperations reduced major bleeding episodes and transfusion needs in valve reoperation patients. This suggests safety and protection, though material-independent factors may limit full benefits.
Area of Science:
- Cardiovascular Surgery
- Biomaterials Science
- Medical Device Engineering
Background:
- Heparin-coated circuits may mitigate systemic inflammatory responses during cardiopulmonary bypass.
- Previous studies in low-risk patients undergoing coronary artery bypass grafting (CABG) showed no clear clinical outcome improvements.
- Cardiac reoperations present a unique patient population where heparin-coated circuits might offer enhanced benefits.
Purpose of the Study:
- To evaluate the efficacy and safety of heparin-coated circuits in patients undergoing cardiac reoperations.
- To compare clinical outcomes between heparin-coated and uncoated circuits in this specific patient group.
- To analyze outcomes in subgroups based on reoperation type (CABG only, valve, or combined).
Main Methods:
- A randomized trial involving 350 patients undergoing cardiac reoperations (CABG-only or valve procedures).
- Patients were assigned to either heparin-coated (Duraflo II) or uncoated cardiopulmonary bypass circuits.
- Clinical outcomes were assessed and analyzed across the entire cohort and specific subgroups.
Main Results:
- No significant difference in overall clinical outcomes between groups.
- A significant reduction in major bleeding episodes was observed in the heparin-coated circuit group (1.2% vs. 5.4%, p=0.035).
- Patients with valve reoperations in the heparin-coated group required fewer blood transfusions in the ICU (p=0.013); a trend towards less reoperation for bleeding was noted in CABG reoperation subgroups (p=0.058).
Conclusions:
- Heparin-coated circuits are safe for cardiac reoperations and offer protection against major bleeding episodes and reoperations for bleeding.
- Material-independent factors, such as blood-air interfaces and cardiotomy suction, can diminish the overall effectiveness of heparin-coated surfaces.
- Further research may be needed to optimize heparin-coated circuit performance in complex cardiac surgical procedures.
Background:
Heparin-coated circuits in cardiopulmonary bypass have been shown to decrease the systemic inflammatory responses associated with cardiopulmonary bypass. Previous clinical studies on low-risk patients who had coronary artery bypass grafting (CABG) and received full-dose systemic heparin did not have clearly improved clinical outcomes. We hypothesized that the beneficial effects of heparin-coated circuits might be seen in patients who had cardiac reoperations.
Methods:
Three hundred fifty patients who had reoperation with CABG only (58%), or with valve operations (42%) were randomly assigned to receive either a heparin-coated (Duraflo II; study group) or uncoated (control group) circuit. Clinical outcomes were compared and the variables were analyzed using the following three groups: entire populations of study group and control group, subgroup of patients who had CABG reoperation only, and a subgroup who had valve reoperation or combined valve and CABG reoperation.
Results:
Preoperative variables were the same in both groups. No difference in clinical outcomes could be demonstrated except that the percentage of patients with major bleeding episodes was significantly lower in the study group (1.2% versus 5.4%, p = 0.035). In the subgroup analysis of patients who had valve reoperations, lower blood transfusion requirements in the intensive care unit (p = 0.013) were found in the study group. When the subgroup of patients who had CABG reoperations was analyzed separately, there was a trend toward less reoperation for bleeding in the study group (0% versus 4.0%, p = 0.058).
Conclusions:
We conclude that the use of heparin-coated circuits was safe and imparted protection from reoperations for bleeding and major bleeding episodes. Material-independent blood activation (eg, blood-air interface and cardiotomy suction) blunted the total effect of the heparin-coated surface.